CIM Investment Management’s Kyntra Bio KYNB Stock Holding History

CIM Investment Management’s Portfolio KYNB Stock Details KYNB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-671	Closed	-$218K	–	252
2022 Q3	$218K	Hold	671	–	–	0.1%	191
2022 Q2	$177K	Hold	671	–	–	0.07%	211
2022 Q1	$202K	Sell	671 -78	-10%	-$27.2K	0.07%	235
2021 Q4	$264K	Hold	749	–	–	0.08%	233
2021 Q3	$191K	Buy	+749	New	+$265K	0.06%	291
2020 Q3	–	Sell	-261	Closed	-$265K	–	267
2020 Q2	$265K	Buy	+261	New	+$242K	0.11%	186
2019 Q4	–	Sell	-228	Closed	-$211K	–	256
2019 Q3	$211K	Hold	228	–	–	0.08%	298
2019 Q2	$257K	Sell	228 -4	-2%	-$4.38K	0.09%	268
2019 Q1	$315K	Sell	232 -2	-0.9%	-$2.71K	0.12%	231
2018 Q4	$271K	Buy	+234	New	+$263K	0.12%	230

Other funds holding KYNB

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

CIM Investment Management's KYNB Position: Q4 2022 in Review

CIM Investment Management sold out of Kyntra Bio (KYNB) in Q4 2022, closing a stake of 671 shares — an estimated $218K sold.

CIM Investment Management first reported a position in KYNB in Q4 2018 and held it in 10 quarters. The position peaked at $315K in Q1 2019. 144 funds tracked by Wall St. Rank hold KYNB as of Q4 2022.

CIM Investment Management reported no remaining Kyntra Bio position as of Q4 2022 after selling out during the quarter.
CIM Investment Management sold 671 Kyntra Bio shares in Q4 2022, an estimated $218K.
CIM Investment Management first reported a position in Kyntra Bio in Q4 2018 and held it in 10 quarters.
CIM Investment Management's Kyntra Bio position peaked at $315K in Q1 2019.
144 funds tracked by Wall St. Rank held Kyntra Bio as of Q4 2022.

Based on CIM Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.